Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2017 Jun;79(6):1161-1167. doi: 10.1007/s00280-017-3312-y. Epub 2017 Apr 26.

Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer.

Author information

1
Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
2
Department of Radiation Oncology, Konyang University College of Medicine, Daejeon, Republic of Korea.
3
Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea. okyu.noh@gmail.com.
4
Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea. okyu.noh@gmail.com.
5
Department of Surgery, Ajou University School of Medicine, Suwon, Republic of Korea.
6
Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
7
Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.

Abstract

PURPOSE:

We aimed to present the clinical outcomes of adjuvant concurrent chemoradiotherapy (CCRT) with low-dose daily cisplatin regimen compared to the conventional 5-fluorouracil (5-FU)-based regimen for extrahepatic bile duct cancer (EHBDC).

METHODS:

From October 1994 to April 2013, 41 patients received adjuvant CCRT with low-dose daily regimen or 5-FU-based regimens. Nineteen patients received low-dose of cisplatin just before every delivery of radiation therapy, and 21 patients received two cycles of 5-FU-based regimen during radiotherapy. We compared the clinical outcomes between two adjuvant CCRT regimens.

RESULTS:

Adjuvant CCRT with low-dose daily cisplatin showed comparable toxicity profiles compared with that of a 5-FU-based regimen. The median follow-up time was 33 months (range, 5-205), and the 5-year overall survival (OS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) were 34.2, 50.8, and 49.7%, respectively. Univariable analyses showed no significant differences in OS, LRRFS, and DMFS between the groups with two regimens. In multivariable analyses, chemotherapeutic regimen was a significant prognostic factor for OS, favoring the low-dose daily cisplatin regimen (HR = 2.491, p = 0.036) over 5-FU-based regimen, though not for LRRFS (p = 0.642) and DMFS (p = 0.756).

CONCLUSIONS:

Adjuvant CCRT with low-dose daily cisplatin regimen showed acceptable toxicities and survivals compared to those of the 5-FU-based regimen. Low-dose daily cisplatin can be one of the feasible regimens for adjuvant CCRT for EHBDC.

KEYWORDS:

5-Fluorouracil; Concurrent chemoradiotherapy; Extrahepatic bile duct cancer; Low-dose daily cisplatin

PMID:
28447209
DOI:
10.1007/s00280-017-3312-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center